Drug Profile

NOV 001

Alternative Names: Hyperoxaluria therapeutic - Novome Biotechnologies; NOV-001

Latest Information Update: 26 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novome Biotechnologies
Class Bacteria; Gene therapies; Polysaccharides
Mechanism of Action Bacteria replacements; Oxalate inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Hyperoxaluria

Most Recent Events

17 May 2023 Novome Biotechnologies discontinues a phase I/II trial in Hyperoxaluria in Canada (PO) as sponsor decided to discontinue the trial (NCT04909723)
17 Nov 2021 Topline efficacy and safety data from a phase I/IIa trial in Hyperoxaluria released by Novome Biotechnologies
02 Jun 2021 Phase-I/II clinical trials in Hyperoxaluria in Canada (PO) (NCT04909723)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com